
Twist Bioscience Posts Fourth-Quarter Loss
The South San Francisco synthetic DNA maker reported a wider loss than last year even as quarterly revenue topped analyst expectations.
For readers in California, this page covers gene editing, drug development and genomics. Reporting follows clinical trials, biotech financing and the approvals that move treatments toward patients.

The South San Francisco synthetic DNA maker reported a wider loss than last year even as quarterly revenue topped analyst expectations.
November 10, 2026
Amyris Cartographer Wins Precision Fermentation AwardAmyris's Cartographer technology received the 2026 BioTech Breakthrough Award for Precision Fermentation Solution of the Year.
November 6, 2026
Azalea Shows In Vivo CAR T Clears Leukemia in MiceBerkeley-based Azalea Therapeutics presented preclinical data on its in vivo TRAC-CAR T cell platform at SITC 2026 in Phoenix.
November 4, 2026
Scribe to Present Heart Therapy Data in ChicagoScribe Therapeutics will share preclinical data on two cardiovascular candidates at the American Heart Association Scientific Sessions in November.
November 3, 2026
California Weighs $8.4 Billion Immunology BondProposition 38 would fund immunology research and therapies through state-authorized bonds, with a 10% revenue requirement intended to repay the state.
November 3, 2026
Bayer Licenses UC Davis Tech for Nitrogen-Fixing GrainsThe licensed method edits grain DNA so plant roots can partner with soil bacteria that convert air nitrogen into a usable form.
November 2, 2026
Solano College Lands $6.55M for Biotech TrainingThe California Institute for Regenerative Medicine approved the funding in September 2026 to expand biotechnology education and workforce training.
November 2, 2026
Drugmaker Wins Tax Offset Ruling in CaliforniaA state tribunal sided with a biopharmaceutical company's use of research tax credits against its 2015 California alternative minimum tax.
November 2, 2026
Voters to Decide on $7.4 Billion Research BondCalifornia's Senate Bill 895 and Proposition 38 would fund biomedical and immunology research after federal grant cuts.
October 30, 2026
Judge Approves $69 Million ChemoCentryx Investor SettlementA federal court settled claims that the biotech company misled investors regarding its vasculitis drug safety profile.
October 30, 2026
California Researchers Receive Grant for Retinal GraftsThe National Eye Institute is funding a project to develop 3D-bioprinted retinal grafts for vision loss.
California biotech reporting spans the gene therapy and CRISPR programs in development, drug approvals, biotech IPOs and acquisitions, and the genomics research that reaches commercial use. Coverage reaches from the Bay Area and San Diego research corridors to the Central Valley and the state's smaller life sciences hubs. Clinical trial design often gets as much scrutiny as the headline result, since the two are easily conflated. Financing cycles and regulatory timelines are the two forces that shape which programs advance and which stall.